ID   FM55p
AC   CVCL_C591
SY   FM55P; FM-55-P; FM 55P
DR   Cosmic; 808536
DR   Cosmic; 972263
DR   Cosmic; 1006223
DR   ECACC; 13012417
DR   ESTDAB; ESTDAB-014
DR   Wikidata; Q54835048
RX   PubMed=7656272;
RX   PubMed=8665567;
RX   PubMed=8968104;
RX   PubMed=9688544;
RX   PubMed=11225993;
RX   PubMed=15592718;
CC   HLA typing: A*01,02; B*15,28; C*03 (PubMed=7656272).
CC   HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*03:04,07:01:01; DPB1*04:01; DQB1*03:02,03:01:01; DRB1*04:02,04:01:01 (PubMed=15592718).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012417; ESTDAB=ESTDAB-014
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 12,13
ST   D3S1358: 14
ST   D5S818: 10,11
ST   D7S820: 8,10
ST   FGA: 24
ST   TH01: 5,7
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C589 ! FM55M1
OI   CVCL_C590 ! FM55M2
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 16
//
RX   PubMed=7656272; DOI=10.1007/BF01527402; PMCID=PMC11037630;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
//
RX   PubMed=8665567; DOI=10.1007/s002620050272; PMCID=PMC11037612;
RA   Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Differential modulation by interferon gamma of the sensitivity of
RT   human melanoma cells to cytolytic T cell clones that recognize
RT   differentiation or progression antigens.";
RL   Cancer Immunol. Immunother. 42:203-212(1996).
//
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
//
RX   PubMed=9688544; DOI=10.1016/S0014-5793(98)00603-6;
RA   Dzhandzhugazyan K.N., Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated
RT   human melanomas.";
RL   FEBS Lett. 430:227-230(1998).
//
RX   PubMed=11225993; DOI=10.1007/s002620000154; PMCID=PMC11036965;
RA   Real L.M., Jimenez P., Kirkin A.F., Serrano A., Garcia A., Canton J.,
RA   Zeuthen J., Garrido F., Ruiz-Cabello Osuna F.;
RT   "Multiple mechanisms of immune evasion can coexist in melanoma tumor
RT   cell lines derived from the same patient.";
RL   Cancer Immunol. Immunother. 49:621-628(2001).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//